Embryonic Signaling Pathways and Rhabdomyosarcoma: Contributions to Cancer Development and Opportunities for Therapeutic Targeting

Table 3

Clinical trials evaluating drugs that target Notch, WNT, or Hedgehog signaling pathways in sarcomas.

ClinicalTrials.gov no.	Indication	Compound	Mechanism	Phase	Start date	Completion date	Sponsor/collaborator
Notch
NCT01154452	Advanced or metastatic sarcoma	RO4929097	Gamma-secretase inhibitor	I/II	Jun 2010	Nov 2010	Memorial Sloan Kettering Cancer Center/NCI
NCT01236586	Relapsed/refractory solid tumors, CNS tumors, lymphoma, T-cell leukemia	RO4929097	Gamma-secretase inhibitor	I/II	Oct 2010	Apr 2011	NCI/NIH CC
WNT
NCT01469975	Synovial sarcoma	OTSA101	Chimeric humanized monoclonal antibody against FZD10	I	Dec 2011	Dec 2013	Centre Leon Berard/OncoTherapy Science, Inc.
Hedgehog
NCT01154452	Advanced or metastatic sarcoma	GDC-0449	Smo small-molecule inhibitor	I/II	Jun 2010	Nov 2010	Memorial Sloan Kettering Cancer Center/NCI
NCT01267955	Advanced chondrosarcoma	GDC-0449	Smo small-molecule inhibitor	II	Dec 2010	Feb 2012	Institut Bergonié/NCI
NCT01310816	Metastatic or unresectable chondrosarcoma	IPI-296	Smo small-molecule inhibitor	II	Feb 2011	Sep 2015	Infinity Pharmaceuticals, Inc.
NCT01125800	Medulloblastoma, rhabdomyosarcoma, neuroblastoma, hepatoblastoma, high-grade glioma, astrocytoma	LDE225	Smo small-molecule inhibitor	I	Feb 2011	Ongoing	Novartis Pharmaceuticals

Obtained from clinicaltrials.gov website January 8, 2012.